Navigation Links
OTC sale for Xenical; Diet Drug; gets FDA approval

Prescription diet drug Xenical manufactured by GlaxoSmithkline got a nod for OTC sale from FDA.It received an "approvable" letter from the Food// and Drug Administration so that it can be marketed once the company addresses additional questions from regulators. An estimated arrival time for the sale is early next year.

It would become the first F.D.A.-approved weight-loss product sold without a doctor's prescription. The diet drug has been christened Alli.

A federal advisory panel voted 11 to 3 in January that the drug, which works by blocking fat absorption, could be sold without a prescription.

Although Xenical has been available as a prescription drug since 1999, it never got the star status partly because about half of the people who use it have episodes of diarrhoea, oily stools and flatulence because of fat that is excreted from the body rather than absorbed.

Clinical studies of the lower-dose over-the-counter version have shown that people using the drug lose more than their counterparts on similar diets who do not take the medication — an average of about five to six additional pounds more over six months. About 18 percent lose 10 percent or more of their initial body weight.

If it wins final approval, it would be the only FDA-endorsed weight-loss drug available without a prescription. But some experts express concern about people regaining weight after they stop using the drug, as well as whether people will be able to tell if it is safe for them without a doctor's advice. The drug can also lead to hepatitis, gallstones and kidney stones, although the exact cause is not clear.

But Gbola Amusa, an analyst in London for Sanford C. Bernstein & Company, said, "I'm assuming that the F.D.A. is addressing some things related to how they can ensure that this drug is not used inappropriately”.

So the diet pill Xenical would soon be seen in shops.


'"/>




Page: 1

Related medicine news :

1. Ranbaxy gets US FDA approval for Lisinopril
2. Aurobindo gets U.S. FDA approval for Cephalexin
3. Cadila gets US FDA approval for Promethazine tablets
4. Anti-obesity drugs for FDA approval
5. Grand FDA nod and approval for drug for heart transplant patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/27/2016)... ... ... More than a third of American adults are considered obese, says the ... increased attention in recent years, as an article published May 18th on ... people are familiar with the basic requirements of maintaining a healthy diet and exercise ...
(Date:5/27/2016)... ... 2016 , ... With over 60 percent of acute stroke survivors being left ... to aid in the rehabilitation process has steadily increased. Ekso Bionics had been working ... due to stroke. , Ekso Bionics has now received clearance from the U.S. Food ...
(Date:5/27/2016)... York, NY (PRWEB) , ... May 27, 2016 ... ... care world, this installment is bolstered by inspiring human interest stories, courtesy of ... the developing trends and tech within the industry, from leading advocates and associations—namely ...
(Date:5/26/2016)... ... ... There are many ways to cook a hot dog, but new research ... their dogs straight off the grill. Of the 90 percent of Americans who say ... a hot dog, far outpacing other cooking methods such as steaming (12 percent), microwaving ...
(Date:5/26/2016)... ... May 26, 2016 , ... Connor Sports, through its Connor Cares ... the Tamika Catchings Legacy Tour that will commemorate the Indiana Fever legend’s ... surfaces in all forms and levels of the game, Connor Sports has committed to ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... study highlights the necessity of health literacy within the technology advancement of diagnostic imaging. According ... , a majority of oncology patients undergo imaging screenings without understanding the nuanced risks ... ... ... Medical Diagnostic Imaging Ampronix ...
(Date:5/27/2016)... , May 27, 2016 ... biopharmaceutical company focused on late-stage drug development, today ... Pharma of pivotal batches required for registration ... Administration (FDA). This follows Kitov,s announcement ... trial successfully met its primary efficacy endpoint. ...
(Date:5/26/2016)... 26, 2016 A key trend ... the emergence of new treatments. Cardax, a development stage ... treatment. The therapy is expected to fulfil large unmet ... is conducting studies to develop new treatments for osteoarthritis. ... genes involved in osteoarthritis are being investigated, and early ...
Breaking Medicine Technology: